Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis

Healthy Clinical Trial

Official title:

Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02187393
• Other study ID #: 13-3027
• Secondary ID: R01HL097163
• Status: Withdrawn
• Phase: N/A
• First received: March 13, 2014
• Last updated: November 25, 2015
• Start date: July 2015
• Est. completion date: November 2015

Study information

• Verified date: November 2015
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The investigators are trying to understand the role of specific genes in the function of airway surface cells. The investigators know that there are some common genetic markers that are associated with various lung diseases. However, most people with these genetic markers never develop any evidence of lung disease, so it is not understand how or if these markers play a role in disease. Investigators are asking healthy people to provide three (3) tubes of blood as well as a sample of cells from their nose. Investigators will use the blood sample to provide genetic information (specifically, presence or absence of alleles known to be associated with pulmonary fibrosis). Nose cells from individuals with the genetic markers that investigators are studying will be grown in the the lab to allow investigators to learn more about how the cells respond to various forms of environmental stress, such as exposure to cigarette smoke. The goal of this study is to understand how specific genes affect airway cell function.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Age greater than 18 years of age

2. Ability to provide informed consent

3. Patent bilateral nares

Exclusion Criteria:

1. Significant nasal or sinus disease precluding nasal brushing

2. A history of or ongoing epistaxis (nose-bleeding)

3. Acute upper respiratory illness

4. Ongoing treatment of respiratory or sinus illness with antibiotics

5. Pregnancy

6. Age less than 18 years

7. Infection with human immunodeficiency virus (HIV) or viral hepatitides (Hepatitis B, Hepatitis C)

8. Prior volunteer for the same study

9. Known diagnosis of cystic fibrosis or other ciliary disorder (example: primary ciliar dyskinesia)

10. Treatment with anticoagulants (examples: warfarin/coumadin, low molecular weight heparins, direct thrombin inhibitors such as dabigatran, anti-platelet agents such as P2Y12 inhibitors like clopidogrel and prasugrel, aspirin, ticagrelor, or factor Xa inhibitors such as rivaroxaban)

11. Known thrombocytopenia (example: immune thrombocytopenic purpura)

12. Ongoing chemotherapy

13. Known platelet dysfunction or bleeding diathesis/hemophilia

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Fibrosis
• Healthy
• Idiopathic Interstitial Pneumonias
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Locations

Country	Name	City	State
United States	University of Colorado Denver	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Epithelial monolayer permeability (protein and cell permeability)	Epithelial monolayer permeability as measured by dextran/protein and neutrophil traffic through monolayer in vitro. This will be measured on epithelial monolayers derived in vitro from cells collected from study subjects. The differentiation of epithelial monolayers can take 3-6 weeks depending on the vagaries of the cell culture technique.	6 weeks.	No
Primary	in vitro epithelial integrity measured by transepithelial electrical resistance (TEER), reported in ohms	The in vitro epithelial cell culture process will take approximately 4-6 weeks after the cells collected are thawed. (At the time of collection from study subjects, cells will be frozen until the time of thawing and culturing.) The in vitro epithelial process will take 6 weeks to differentiate epithelial monolayers at which time the tests of epithelial integrity can be performed. Study subjects themselves are not being followed.	6 weeks	No
Secondary	gene expression (DSP, MUC5B, genes associated with ER Stress), reported as "fold-change" or "CT mean"	Gene expression assays (designed by Taqman/Life Technologies) will be used to examine expression of genes that we believe are associated with pulmonary fibrosis -- specifically, various mucins (MUC5B, MUC5AC, DSP, and numerous genes associated with endoplasmic reticulum (ER) stress). This will be measured on epithelial monolayers derived in vitro from cells collected from study subjects. The differentiation of epithelial monolayers can take 3-6 weeks depending on the vagaries of the cell culture technique.	6 weeks	No